StatePharma expands international supplier network through new deal with Bangladesh’s HPL

State Pharmaceuticals has signed a distribution agreement with Healthcare Pharmaceuticals Ltd. (HPL), a world-renowned pharmaceutical manufacturer, as part of its efforts to strengthen the national health system and ensure access to quality medicines across the country.

The company said the agreement marks an important step toward securing uninterrupted availability of essential medicines and further reinforcing the Maldives’ pharmaceutical supply chain. State Pharmaceuticals noted that expanding partnerships with reputable international suppliers is central to its strategy to improve procurement efficiency and strengthen all stages of the supply chain.

The agreement is also a major milestone in the company’s work to provide easy access to basic medicines and introduce high-quality pharmaceutical products to the Maldivian market.

HPL is a trusted name in the global pharmaceutical industry. Its products are exported to more than 32 countries, including markets in Europe, Asia, Africa and the United States. Based in Bangladesh, the company began operations in collaboration with Roche (Switzerland) and currently manufactures over 200 generic and specialized medicines across multiple therapeutic classes. HPL recently signed an agreement with AstraZeneca, one of the United Kingdom’s largest pharmaceutical companies.

One of the biggest concerns for the public has long been the difficulty of obtaining medicines. People often have to visit multiple pharmacies without success, and if the medicines are not covered under Aasandha, they end up paying significantly more out of pocket.

State Pharmaceuticals was established to address these complaints and resolve persistent shortages. The company announced that it began importing medicines in April, six months after its inception.